{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T07:04:58Z","timestamp":1779433498612,"version":"3.53.1"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Preeclampsia seriously threatens maternal and infant health. Antihypertensive therapy is key to improving perinatal outcomes, yet comparative maternal-fetal evidence for oral agents remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare maternal\u2013fetal outcomes of oral labetalol versus oral nifedipine in preeclampsia, informing individualized clinical treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study included consecutive preeclampsia patients admitted from January 2023 to December 2025, divided into Labetalol (n = 154) and nifedipine (n = 136) groups. Both received magnesium sulfate as needed, plus aspirin or low-molecular-weight heparin based on platelet count and coagulation function. After 1:1 propensity score matching (PSM), maternal and fetal outcomes were compared. Primary outcomes were maternal complications and neonatal outcomes. Secondary outcomes included uterine artery blood flow, hemodynamics, fetal growth restriction, and adverse drug reactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Following PSM, baseline characteristics were comparable between the two groups (P &amp;gt; 0.05). Both achieved similar improvements in blood pressure, uterine artery blood flow (S\/D, PI, RI), and hemodynamic indicators (plasma and whole blood viscosity, hematocrit) (P &amp;gt; 0.05). The Labetalol Group, compared to the nifedipine Group, had significantly lower rates of postpartum hemorrhage (8.8% vs. 17.0%, P = 0.043) and preterm birth (24.6% vs. 37.3%, P = 0.041), and higher neonatal birth weight (2933.95 \u00b1 803.23\u00a0g vs. 2541.35 \u00b1 631.41\u00a0g, P &amp;lt; 0.001). Conversely, the nifedipine Group experienced higher incidences of headache (16.4% vs. 7.3%, P = 0.037) and facial flushing (13.6% vs. 4.6%, P = 0.019). Multivariate Logistic regression identified maternal age \u226535 years, pre-pregnancy overweight\/obesity, preeclampsia onset at &amp;lt;34 weeks, primiparity, multiple pregnancy, severe preeclampsia, and pre-gestational diabetes as independent risk factors for adverse maternal-fetal outcomes (all P &amp;lt; 0.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Both labetalol and nifedipine effectively control blood pressure and improve uteroplacental blood flow and most maternal-fetal outcomes in patients with preeclampsia. Adverse effects (headache and facial flushing) were more commonly observed with nifedipine, whereas labetalol was associated with a lower incidence of preterm birth and postpartum hemorrhage. These findings suggest potential advantages of labetalol in specific outcomes, but causal inferences are limited by the observational study design.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1832562","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T06:08:24Z","timestamp":1779430104000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative maternal-fetal outcomes associated with different antihypertensive treatment strategies in preeclampsia: a retrospective cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Lin","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Obstetrics, Henan Provincial People\u2019s Hospital","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Henan Provincial People\u2019s Hospital","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahui","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Henan Provincial People\u2019s Hospital","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiying","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Henan Provincial People\u2019s Hospital","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"309","DOI":"10.5281\/zenodo.18264846","article-title":"Comparison of therapeutic effect of labetalol with nifedipine in control of hypertensive disorders of pregnancy","volume":"7","author":"Ajit Kumar Gupta","year":"2026","journal-title":"Int. J. Med. Pharm. Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"102437","DOI":"10.1016\/j.bpobgyn.2023.102437","article-title":"Pharmacogenomics of preeclampsia therapies: current evidence and future challenges for clinical implementation","volume":"92","author":"Chaemsaithong","year":"2024","journal-title":"Best Pract. and Res. Clin. Obstet. and Gynaecol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s41043-025-00778-6","article-title":"Prevalence, risk factors, and adverse perinatal outcomes in Chinese women with preeclampsia: a large retrospective cohort study","volume":"44","author":"Chai","year":"2025","journal-title":"J. Health Popul. Nutr."},{"key":"B4","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.3390\/ijms25084532","article-title":"The pathophysiological, genetic, and hormonal changes in preeclampsia: a systematic review of the molecular mechanisms","volume":"25","author":"Chiang","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1161\/CIRCRESAHA.124.325581","article-title":"Advances in our understanding of cardiovascular diseases after preeclampsia","volume":"136","author":"Countouris","year":"2025","journal-title":"Circ. Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(19)31282-6","article-title":"Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial","volume":"394","author":"Easterling","year":"2019","journal-title":"Lancet London, Engl."},{"key":"B7","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.placenta.2012.07.011","article-title":"Beyond the placental bed: placental and systemic determinants of the uterine artery Doppler waveform","volume":"33","author":"Everett","year":"2012","journal-title":"Placenta"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1097\/HJH.0000000000003233","article-title":"Comparative efficacy and safety of oral nifedipine with other antihypertensive medications in the management of hypertensive disorders of pregnancy: a systematic review and meta-analysis of randomized controlled trials","volume":"40","author":"George","year":"2022","journal-title":"J. Hypertens."},{"key":"B9","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1097\/AOG.0000000000003891","article-title":"Gestational hypertension and preeclampsia: ACOG practice bulletin, number 222","volume":"135","year":"2020","journal-title":"Obstet. Gynecol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"84","DOI":"10.9734\/jammr\/2021\/v33i2131136","article-title":"The effect of methyl Dopa, nifedipine and labetalol treatment on uterine, umbilical and fetal middle cerebral artery blood flows in cases suffered from pregnancy induced hypertension","volume":"33","author":"Hassan","year":"2021","journal-title":"J. Adv. Med. Med. Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.ajog.2025.04.011","article-title":"Oral antihypertensive treatment during pregnancy: a systematic review and network meta-analysis","volume":"233","author":"Hup","year":"2025","journal-title":"Am. J. Obstet. Gynecol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e001567","DOI":"10.1136\/bmjpo-2022-001567","article-title":"Incidence of adverse perinatal outcomes and risk factors among women with pre-eclampsia, southern Ethiopia: a prospective open cohort study","volume":"6","author":"Jikamo","year":"2022","journal-title":"BMJ Paediatr. Open"},{"key":"B13","doi-asserted-by":"publisher","first-page":"102054","DOI":"10.1016\/j.jacadv.2025.102054","article-title":"Comparative effectiveness and safety of labetalol versus nifedipine for treatment of chronic hypertension during pregnancy","volume":"4","author":"Leonard","year":"2025","journal-title":"JACC Adv."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.64229\/th2dwv31","article-title":"Treatment as prevention: a review of the use of traditional Chinese medicine in high-risk diabetic foot","volume":"1","author":"Li","year":"2025","journal-title":"Nurs. Sci. Clin. Pract."},{"key":"B15","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/jch.14176","article-title":"Impact of gestational hypertension and preeclampsia on low birthweight and small-for-gestational-age infants in China: a large prospective cohort study","volume":"23","author":"Liu","year":"2021","journal-title":"J. Clin. Hypertens. (Greenwich, Conn)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.63623\/k3v38d32","article-title":"The relationship of blood glucose with early morbidity, mortality, and other prognostic factors in pancreatic cancer","volume":"1","author":"Ozer","year":"2025","journal-title":"Adv. Mod. Biomed."},{"key":"B17","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1055\/s-0038-1660777","article-title":"Uterine artery doppler in screening for preeclampsia and fetal growth restriction","volume":"40","author":"Pedroso","year":"2018","journal-title":"Rev. Bras. Ginecol. Obstet. Rev."},{"key":"B18","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1891\/NN-2024-0001","article-title":"Short- and long-term effects","volume":"43","author":"Preeclampsia","year":"2024","journal-title":"Neonatal Netw. NN"},{"key":"B19","doi-asserted-by":"publisher","first-page":"h61","DOI":"10.1152\/ajpheart.00202.2020","article-title":"Vascular mechanisms and molecular targets in hypertensive pregnancy and preeclampsia","volume":"319","author":"Qu","year":"2020","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.3390\/ijms20133263","article-title":"Preeclampsia: the relationship between uterine artery blood flow and trophoblast","volume":"20","author":"Ridder","year":"2019","journal-title":"Function"},{"key":"B21","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.ecl.2024.05.012","article-title":"Update on preeclampsia and hypertensive disorders of pregnancy","volume":"53","author":"Rosenberg","year":"2024","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.12688\/f1000research.125944.2","article-title":"Effectiveness of nifedipine, labetalol, and hydralazine as emergency antihypertension in severe preeclampsia: a randomized control trial","volume":"11","author":"S","year":"2022","journal-title":"F1000Research"},{"key":"B23","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/AOG.0000000000005613","article-title":"Pregnancy outcomes of nifedipine compared with labetalol for oral treatment of mild chronic hypertension","volume":"144","author":"Sanusi","year":"2024","journal-title":"Obstet. Gynecol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"s22","DOI":"10.1016\/j.ajog.2020.08.018","article-title":"Guidelines-similarities and dissimilarities: a systematic review of international clinical practice guidelines for pregnancy hypertension","volume":"226","author":"Scott","year":"2022","journal-title":"Am. J. Obstet. Gynecol."},{"key":"B25","first-page":"601","article-title":"Effectiveness and safety assessment of beta-blockers, calcium channel blockers, and angiotensin receptor blockers in hypertensive patients: a prospective study","volume":"11","author":"Solanki","year":"2021","journal-title":"Am. J. Cardiovasc. Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1007\/s43032-024-01765-8","article-title":"Voltage-gated calcium channels and the parity-dependent differential uterine response to oxytocin in rats","volume":"32","author":"Sondgeroth","year":"2025","journal-title":"Reprod. Sci. (Thousand Oaks, Calif.)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e15193","DOI":"10.1097\/MD.0000000000015193","article-title":"First trimester Doppler velocimetry of the uterine artery ipsilateral to the placenta improves ability to predict early-onset preeclampsia","volume":"98","author":"Song","year":"2019","journal-title":"Medicine"},{"key":"B28","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1186\/s12884-022-04854-1","article-title":"Tocolysis with nifedipine versus atosiban and perinatal outcome: an individual participant data meta-analysis","volume":"22","author":"van Winden","year":"2022","journal-title":"BMC Pregnancy Childbirth"},{"key":"B29","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.preghy.2020.03.006","article-title":"Adverse maternal and neonatal outcomes among women with preeclampsia with severe features <34 weeks gestation with versus without comorbidity","volume":"20","author":"Venkatesh","year":"2020","journal-title":"Pregnancy Hypertension"},{"key":"B30","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1161\/HYPERTENSIONAHA.117.09972","article-title":"Labetalol Versus nifedipine as antihypertensive treatment for chronic hypertension in pregnancy: a randomized controlled trial","volume":"70","author":"Webster","year":"2017","journal-title":"Hypertens. (Dallas, Tex 1979)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41371-021-00497-5","article-title":"Comparison of the effects on maternal endothelial cell activation: an in vitro study of anti-hypertensive drugs clinically used in pre-eclampsia","volume":"36","author":"Woolston","year":"2022","journal-title":"J. Hum. Hyperten."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e071653","DOI":"10.1136\/bmj-2022-071653","article-title":"Hypertensive disorders of pregnancy","volume":"381","author":"Wu","year":"2023","journal-title":"BMJ (Clin. Research Ed)"},{"key":"B33","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1186\/s12884-024-06497-w","article-title":"Comparison of the efficacy of nifedipine with ritodrine, nitroglycerine and magnesium sulfate for the management of preterm labor: a systematic review and meta-analysis","volume":"24","author":"Zamani","year":"2024","journal-title":"BMC Pregnancy Childbirth"},{"key":"B34","doi-asserted-by":"publisher","first-page":"Cd003654","DOI":"10.1002\/14651858.CD003654.pub5","article-title":"Calcium channel blockers versus other classes of drugs for hypertension","volume":"10","author":"Zhu","year":"2021","journal-title":"Cochrane Database Syst. Rev."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1832562\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T06:08:26Z","timestamp":1779430106000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1832562\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":34,"alternative-id":["10.3389\/fphar.2026.1832562"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1832562","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"article-number":"1832562"}}